Allergic Conjunctivitis - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 57 pages report, published by Global Markets Direct

Keywords : Allergic Conjunctivitis Therapeutic Products under Development, Key Players in Allergic Conjunctivitis Therapeutics, Allergic Conjunctivitis Pipeline Overview, Allergic Conjunctivitis Pipeline, Allergic Conjunctivitis Pipeline Assessment

Report ThumbnailSeptember-2013
Allergic Conjunctivitis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Allergic Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Allergic Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis. Allergic Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Allergic Conjunctivitis.
- A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Allergic Conjunctivitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Allergic Conjunctivitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Allergic Conjunctivitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Allergic Conjunctivitis, H2 2013 8
  • Products under Development for Allergic Conjunctivitis - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Late Stage Products, H2 2013 12
  • Mid Clinical Stage Products, H2 2013 13
  • Early Clinical Stage Products, H2 2013 14
  • Pre-Clinical Stage Products, H2 2013 15
  • Assessment by Monotherapy Products, H2 2013 24
  • Assessment by Combination Products, H2 2013 25
  • Assessment by Route of Administration, H2 2013 26
  • Assessment by Stage and Route of Administration, H2 2013 27
  • Assessment by Molecule Type, H2 2013 28
  • Assessment by Stage and Molecule Type, H2 2013 29
  • List of Tables
  • Number of Products Under Development for Allergic Conjunctivitis, H2 2013 8
  • Products under Development for Allergic Conjunctivitis - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 11
  • Comparative Analysis by Late Stage Development, H2 2013 12
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 14
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 15
  • Products under Development by Companies, H2 2013 16
  • Boehringer Ingelheim GmbH, H2 2013 17
  • Allergan, Inc., H2 2013 18
  • Sanofi-Aventis, H2 2013 19
  • Sun Pharmaceutical Industries Limited, H2 2013 20
  • LABORATOIRES THEA, H2 2013 21
  • Morria Biopharmaceuticals Plc, H2 2013 22
  • Laila Pharmaceuticals Pvt. Ltd., H2 2013 23
  • Assessment by Monotherapy Products, H2 2013 24
  • Assessment by Combination Products, H2 2013 25
  • Assessment by Stage and Route of Administration, H2 2013 27
  • Assessment by Stage and Molecule Type, H2 2013 29
  • Allergic Conjunctivitis Therapeutics - Drug Profile Updates 45
  • Allergic Conjunctivitis Therapeutics - Discontinued Products 47
  • Allergic Conjunctivitis Therapeutics - Dormant Products 48
  • Allergic Conjunctivitis Therapeutics - Dormant Products (Contd..1) 49
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Allergic Conjunctivitis Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Allergic Conjunctivitis 8
  • Allergic Conjunctivitis Therapeutics under Development by Companies 10
  • Late Stage Products 12
  • Comparative Analysis 12
  • Mid Clinical Stage Products 13
  • Comparative Analysis 13
  • Early Clinical Stage Products 14
  • Comparative Analysis 14
  • Pre-Clinical Stage Products 15
  • Comparative Analysis 15
  • Allergic Conjunctivitis Therapeutics - Products under Development by Companies 16
  • Companies Involved in Allergic Conjunctivitis Therapeutics Development 17
  • Boehringer Ingelheim GmbH 17
  • Allergan, Inc. 18
  • Sanofi-Aventis 19
  • Sun Pharmaceutical Industries Limited 20
  • LABORATOIRES THEA 21
  • Morria Biopharmaceuticals Plc 22
  • Laila Pharmaceuticals Pvt. Ltd. 23
  • Allergic Conjunctivitis - Therapeutics Assessment 24
  • Assessment by Monotherapy Products 24
  • Assessment by Combination Products 25
  • Assessment by Route of Administration 26
  • Assessment by Molecule Type 28
  • Drug Profiles 30
  • (prednisolone + cyclosporine) - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • OC-459 - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • AC-150 - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • OPX-1 - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • SUN-1334 H - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • SUN-1334 H - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • AC-170 - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • T-1210 - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • epinastine - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • Histamine H1/H4 Receptor Antagonist - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • AGN-229666 - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • LP-002-09 - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • Allergic Conjunctivitis Therapeutics - Drug Profile Updates 45
  • Allergic Conjunctivitis Therapeutics - Discontinued Products 47
  • Allergic Conjunctivitis Therapeutics - Dormant Products 48
  • Allergic Conjunctivitis - Product Development Milestones 50
  • Featured News & Press Releases 50
  • Apr 17, 2013: Celsus Therapeutics Receives US Patent Covering Product Candidate OPX-1 For Treatment Of Conjunctivitis 50
  • Nov 27, 2012: Santen Pharma Files For Manufacturing And Marketing Approval Of Anti-Allergic Ophthalmic Solution, DE-114 50
  • Oct 25, 2012: Zalicus Licensee, Sanofi, Provides Status Update On Prednisporin 51
  • Jul 02, 2012: Faes Farma Receives Approval For Bilastine In Mexico 51
  • Mar 22, 2011: ISTA Pharmaceuticals Highlights BEPREVE Clinical Data At 2011 American Academy of Allergy, Asthma and Immunology Annual Meeting 51
  • Nov 26, 2010: Restasis gets Health Canada approval 52
  • Jun 07, 2010: CombinatoRx Receives Milestone Payment For Prednisporin Advancement 52
  • Jun 07, 2010: New Efficacy Data Emphasize The Benefit Of Pollinex Quattro Grass 53
  • May 05, 2010: Foresight Announces Encouraging Data From FST-100 Study In Adenoviral Conjunctivitis Model 53
  • Dec 07, 2009: Stallergenes Announces Positive Three-Year Results Of Phase III Trial With Oralair 54
  • Appendix 56
  • Methodology 56
  • Coverage 56
  • Secondary Research 56
  • Primary Research 56
  • Expert Panel Validation 56
  • Contact Us 57
  • Disclaimer 57

Please select a license type

Share

Related Products

Global Markets DirectAllergic Conjunctivitis - Pipeline Review, H2 2013Product ThumbnailAllergic Conjunctivitis - Pipeline Review, H2 2013, Industry ReportProduct #: 113301
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved